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Hypericum perforatum L. (Hypericaceae) has been widely prescribed for mild to moderate
depression following the release of promising results in clinical trials. However, it is known
that its constituents may be affected by milieu. The stability complexities of the constit-
uents of H. perforatum have gained interest in recent years. The aim of the present study
was to examine the impact of storage conditions on H. perforatum total extract simulta-
neously under different storage conditions. Temperature, humidity, and light conditions
were evaluated. Comparative analyses of methanol extracts were conducted using high
performance liquid chromatography-diode array detection for chlorogenic acid, rutin,
hyperoside, isoquercitrin, quercitrin, quercetin, amentoflavone, pseudohypericin, hyper-
forin, and hypericin. Analysis and extraction were performed using a validated method.
The fluctuation of the constituents of the plant extract has been demonstrated. Among
these components, chlorogenic acid was the most stable. Hyperforin, hypericin, and
pseudohypericin were more stable than the flavonoids at 20C, in the 6th month. As
estimated, decay was lowest at 20C and highest at 40Ce75% relative humidity for the
analyzed constituents. Except for hyperforin, light protection decreased the breakdown of
components within 4 months. However, at the 6th month, equivalent changes were seen
for all constituents. Degradation of the constituents at 20C indicates the importance of
stability tests in analysis studies covering time and storage conditions.
Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.
 
Open access under CC BY-NC-ND license.1. Introduction
Plants and their preparations have been used by humans in
the treatment of various conditions for thousands of years.
Use of traditional medicine including medicinal plants
remains widespread in developing countries, whereasmaceutical Botany, Facul
du.tr (M.Z. Haznedaroglu
ministration, Taiwan. Publcomplementary and alternative medicine use continue to
thrive in developed countries [1]. Investigations support
complementary and alternative medicine for physical and
psychiatric disorders [2]. Thus, medicinal plants are still being
widely studied in contemporary pharmaceutical sciences.
Hypericum perforatum L. (HP) has been used for centuries. Its
efficacy and indications of use have been well documented byty of Pharmacy, Ege University, Ankara Cad. No: 172/98 Kampus,
).
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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followed by Paracelsus [3], and today it is compiled in various
pharmacopeias such as European Pharmacopeia, European
Scientific Cooperative on Phytotherapy (ESCOP) European
Medicines Agency, and World Health Organization Mono-
graphs. Commonly, HP has been indicated internally as an
antidepressant and used as a wound healer agent externally.
Popular products based on this plant, which are used for the
treatment of mild and moderate depression, account for a
substantial market share in the United States; additionally, it
has been prescribed more often than fluoxetine HCl in Ger-
many [4]. HP is a plant tested in numerous clinical trials [5],
providing a high level of evidence results [6], whereas it is
classified as the most commonly used species in ethnobotan-
ical surveys [7]. In the search for new compounds, quantifica-
tion of constituents, extract optimization, and standardization
of Hypericum species is an important topic [8e11].
Stability tests have been an important part of the testing
program for both drug substances and herbal preparations.
Recently, investigations on the stability of commonly used
herbal extracts have drawn increasing attention [12e15]. Sta-
bility is an important issue for HP, which has complex in-
gredients: hypericin, pseudohypericin (naphthodianthrones);
hyperforin (phloroglucinol); hyperoside, quercitrin, quercetin,
rutin (flavonoids); and chlorogenic acid (phenolic acids) [16].
Previous reports have demonstrated someproblems in relation
to the stability of HP extracts. In a study, interdays stability and
effects of filtration on major constituents of methanol extract
weredetermined [17]. Inanother study,hyperforinstabilitywas
studied on the lipophilic fraction of extract analyzed using
high-performance liquid chromatography (HPLC)emass spec-
trometry (MS) [18]. The stability of HP oils prepared with
different methods was analyzed using the HPLC-diode array
detection (DAD)eMS system [13]. Flavonoids, naphthodian-
thrones, and phloroglucinol derivatives were evaluated in
tincture with HPLC-DADeMS for accelerated and long-term
testing [12]. The stability of hyperforin in maceration of HP
dried flowers was also determined using the HPLC system [19].
The thermal and photostability of commercial dried extract
was investigated according to the International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) testing conditions [16].
Marketed formulations were analyzed for their hypericin and
pseudohypericin content concerning temperature and humid-
ity [20]. The relation between physical and chemical charac-
teristics was likewise examined for HP products [21]. The
stability of hypericin and pseudohypericin in extracts of
Hyperici herba and standard solutions were studied under
different temperatures and light conditions; the results were
monitoredwith visible spectroscopyandHPLC-VIS/DAD [22]. In
another study, the content uniformity of the plant and batch-
to-batch reproducibility in HP products were investigated [23].
All these studies have important contributions to what we
know about extract stability. However, the stability of dried
total extract still has complexity and requires further clarifi-
cation in terms of gathering conditions in one investigation
concerning storage parameters such as light, humidity, and
temperature together in parallel control. Therefore, the studied
parameters were chosen to simulate the conditions usually
encountered such as the effects of light, preservation capabilityof cold storage, and the effects of heat and humidity at rough
levels to observe the degradation according to ICH guidelines.
To the best of our knowledge, this is the first investigation to
cover all themajor constituents regarding the impact of storage
conditions on H. perforatum dried total extract, including such
parameters ashumidity, light, and temperature for 6months in
the same context.
In this study, our aim was to determine the impact of
storage conditionsdsuch as temperature, humidity, and light
conditionsdon the constituents of Hypericum perforatum
methanolic extract (HPME). Analyses were carried out using
the HPLC-DAD system for these components.2. Methods
2.1. General
HPLC-grade water was obtained with Millipore Type I Ultra-
pureWaterSystems (Millipore, Billerica,MA,USA).HPLC-grade
acetic acid was purchased from J.T. Baker (Center Valley, PA,
USA); HPLC-grade acetonitrile and methanol were purchased
from Labscan (Gliwice, Poland). HPLC standards as hypericin
and pseudohypericin were obtained from Planta Natural
Products (Vienna, Austria). Rutin, quercitrin, quercetin, and
amentoflavone standardswere kindly sent by Professor Hasan
Kırmızıbekmez (Yeditepe University, Istanbul, Turkey);
hyperoside and isoquercitrin standards were kindly given by
Professor Emrah Kılınc¸ (Ege University, Izmir, Turkey), and
hyperforin standard was kindly supplied by Professor Atha-
nassios Giannis (Leipzig University, Leipzig, Germany).
2.2. Plant material
The plant material, collected from a single population of
cultivated plants, was kindly provided by the Faculty of Agri-
culture, Ege University. The plant was identified at the
Department of Pharmaceutical Botany, Faculty of Pharmacy,
Ege University, and specimen vouchers are kept at the IZEF
Herbarium, (Ege University Faculty of Pharmacy International
Herbarium) (No. 5796).
2.3. Extraction method
Air-dried aerial parts of the plant (200 mg) were homogenized
using a blender andwere extractedwith 10mL ofmethanol by
sonication at 11e13C for 30 minutes and at 21e23C for 30
minuteswith exclusion of light. The sampleswere centrifuged
at 7000g for 10 minutes. The supernatant was separated, and
the same procedure was repeated three more times for the
precipitate according to Li and Fitzloff's [17] extraction
method. Dry total extract was obtained via evaporation of
total solvent using a vacuum evaporator. Total dryness of the
extract was achieved using a vacuum concentrator system
(yield: 26.5%, w/w).
2.4. Validation of extraction
Validation tests of blank extraction (an extraction procedure
done without plant material), spiked blank extraction (blank
Table 2 e Gradient analysis system.
Mobile phase (minute) 0 10 30 40 55 56 65
99.7% watere0.3% acetic acid 100 85 70 10 5 100 100
Acetonitrile 0 15 20 75 80 0 0
Methanol 0 0 10 15 15 0 0
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material), reproducibility, repeatability, consistency, and ho-
mogeneity (homogeneity of dry extracts in sample tubes from
five different points of the tubes) were performed. The re-
covery test was performed with Morin standard, which could
be identified with the same analysis method.
2.5. Storage conditions
Storage conditions were determined as follows: room condi-
tion (climatized condition at 25Cwith uncontrolled humidity)
with daylight (case 1) and room condition without daylight,
dark (case 2); 25Ce65% relative humidity (RH; case 3) and
40Ce75% RH (case 4); and20C (case 5) and 4C (case 6; Table
1). For all conditions, three sets of dry extract samples in glass
vials were located and analyzed by HPLC (n ¼ 3) by preparing
fresh samples in each period. The effects of light, tempera-
ture, and humidity were studied monthly for 6 months ac-
cording to the ICH Guidelines [24]. The impact of storage
conditionswas comparedwithin light conditions, cold storage
environment, and ICH guidelines criteria.
2.6. Analysis method
Analyses were performed using the method described by
Brolis et al [25], with minor modifications. Analyses were
conducted using an Agilent 1100 HPLC system equipped with
degasser, autosampler, column oven, gradient pump, and PDA
detector (Agilent Technologies, Waldbronn, Germany). A col-
umn with 4.6 mm diameter, 250 mm length, and 5 mm C18
particle size (ACE-121-2546) is used with 1 cm guard column
5C18 (HI-5C18-10C). The injection volume was 20 mL, and the
flow rate was 1 mL/min. The column oven was set at 30C; the
wavelength was set at 270 nm and 590 nm. The gradient
system of the mobile phase is given in Table 2.
The calibration was studied with seven concentration
points of five injections for chlorogenic acid (1.25e80 mg/mL),
rutin (1e64 mg/mL), hyperoside (2.5e160 mg/mL), isoquercitrin
(1.25e80 mg/mL), quercitrin (0.5e32 mg/mL), quercetin
(0.25e16 mg/mL), amentoflavone (0.125e8 mg/mL), pseudohy-
pericin (0.25e16 mg/mL), hypericin (0.25e16 mg/mL), and
hyperforin (2.5e160 mg/mL) with regression (r2) of > 0.9994.3. Results and discussion
H. perforatum L. has been widely prescribed following the
release of promising results in clinical trials [4]. Consequently,Table 1 e Storage conditions.
Case Condition Aim of investigation
1 25Cddaylight Effect of light
2 25Cddark
3 25Ce65% RH Effect of temperature and humidity
4 40Ce75% RH
5 20C Effect of cold storage
6 4C
RH ¼ relative humidity.the stability complexity of HP compounds has attracted great
interest. In this study, HPME constituents were evaluated for
the interpretation of stability considering different storage
conditions including the effect of light, cold storage condi-
tions, and ICH guidelines criteria.
Validation tests on extractionandanalysiswereperformed.
Tests of blankandquercetin spikedblankextraction continued
with recovery test. Morin as an external compound similar to
analyzed constituents was used for recovery tests, achieving
90% recovery. Extraction repeatability tests gave the following
relative standard deviation (RSD) values: chlorogenic acid,
2.1%; rutin, 4.6%; hyperoside, 2.3%; isoquercitrin, 3.8%; quer-
citrin, 7.8%; quercetin, 14%; amentoflavone, 17.8%; pseudohy-
pericin, 16%; hyperforin, 3.4%; and hypericin, 15.3%. The
homogeneity of thedry extractwasalso tested; considering the
part taken from the sample tube thatwas analyzed could affect
the results. Samples fromfivedifferentpointsof adryextract in
a test tube were analyzed, and results showed that hyperforin
had 10.6% RSD and hypericin had 11.0% RSD, whereas the
maximum RSD was observed for quercetin at 16.8%. To clarify
if any components were left after the extraction procedure,
extraction of disposed precipitates was performed. Hyperforin
and hypericin were not detected; only rutin, hyperoside, and
isoquercitrin (with maximum 8.6%) were calculated.
HPME was examined for phloroglucinols (hyperforin),
naphtodianthrones (hypericin, pseudohypericin), flavonoids
(rutin, hyperoside, isoquercitrin, quercitrin, quercetin, and
amentoflavone), and quinic acid derivative (chlorogenic acid).
The analysis was performed using HPLC-DAD (n ¼ 9) every
month for a period of 6 months. Validation of the analysis
conditionsdinjection repeatability (maximum for hypericin
0.06% RSD), stability of reference standards in a day
(maximum for hyperforin 1.7% RSD) and interdays (maximum
for hypericin 21% RSD)dwas performed. The chromatogram
and RT values are given in Figs. 1 and 2. All 10 compounds
were in the same exact order as in the other studies with
aspect of retention time (RT) (Figs. 1 and 2) [13,17,25]. The
analyzed amounts of the components are in accordance with
the literature data [13,17,25]. Only the amounts of hypericins
and hyperforin were observed to have increased as the stud-
ied plant material was collected from a cultivated plant pop-
ulation of a composition enrichment study.
Results of the analysis for 6 months are summarized in
Tables 3e5, within corresponding cases.
Mainly hypericin has been indicated as the marker com-
pound of the plant to be standardized with in pharmacopeias,
monographs, and related literature [1,5]. However, recent
studies have shown that all constituents might directly or indi-
rectly contribute to bioactivity [12,16,20,21]. Considering this
controversy, all constituents in the total extract were regarded
within commonly encountered conditions in our study.
Storage conditions were determined as follows: room
condition with daylight (case 1) and room condition without
Fig. 1 e HPLC profile of MeOH extract of Hypericum perforatum L., monitored at 270 nm: RT¼ 14.11 minutes, chlorogenic acid
I; RT¼ 22.71 minutes, rutin II; RT¼ 23.64 minutes, hyperoside III; RT¼ 24.92 minutes, isoquercitrin IV; RT¼ 28.79 minutes,
quercitrin V; RT¼ 36.56 minutes, quercetin VI; RT¼ 37.93 minutes, amentoflavone VII; and RT¼ 51.63 minutes, hyperforin
VIII. HPLC ¼ high performance liquid chromatography; RT ¼ retention time.
Fig. 2 e HPLC profile of MeOH extract of Hypericum perforatum L., monitored at 590 nm: RT¼ 45.87minutes, pseudohypericin
IX; and RT ¼ 50.91 minutes, hypericin X. HPLC ¼ high performance liquid chromatography; RT ¼ retention time.
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(case 4); 20C (case 5) and 4C (case 6). The conditions were
chosen to investigate the effects of temperature, humidity,
and light. The effect of light on HPME was observed in case 1
and case 2. Cases 3 and 4 were set up to investigate the per-
centage of degradation, based on ICH guidelines [24]. Climate
cabins were used to show the effect of heat and humidity on
the percentage of degradation under extreme conditions. The
potential protective effect of cold (low) temperatures on the
stability of components was examined at 20C and 4C. The
results are compiled within relevant cases.
Under light and dark room conditions, all compounds
except chlorogenic acid degraded by > 24% within 4 months
(results are presented in Table 3). At the end of the 4th month,
keeping the extract in the dark at room condition led to a
significant improvement in the stability of pseudohypericin,
but not for hypericin and hyperforin. Flavonoids, except
hyperoside, were highly durable for 4 months in the dark at
room condition, but lost their stability at the 6thmonth in both
dark and light conditions. The dark condition provided
improved stability when compared to light for 4 months. At
the 6thmonth, the degradative effect of time overwhelmed the
protective effect of dark on the stability of flavonoids.Under the 25Ce65% RH and 40Ce75% RH conditions,
flavonoids and chlorogenic acid degraded more than hyper-
icin and hyperforin did between the 4th month and 6th month
(Table 4). Therefore, the discussion of our study mainly
focused on the values of the 4th month and 6th month. At
25Ce65% RH, the degradation percentages were similar to
those at room condition with or without daylight. The
extreme condition of 40Ce75% RH gave the highest degra-
dation values. Pseudohypericin, hypericin, and hyperforin
were the compounds that degraded themost in 40Ce75% RH,
reaching values of 65%, 85%, and 69%, respectively, at the end
of the 6th month. Increase in humidity and temperature
enhanced the degradation.
The breakdown of pseudohypericin and hypericin was
close at the end of the 4th month for both 20C and 4C as
presented in Table 5. By contrast, at the 6th month, differen-
tiation in 20C resembled that in 25Ce65% RH. At the 4th
month for 20C, 4C, and dark room conditions, similar re-
sults were observed for pseudohypericin and hyper-
osidedshowing that cold conditions could not provide
significant protective effects for 4 months. Flavonoids (except
hyperoside) were more stable at 20C compared to 4C for 4
months; however, at the end of the 6th month the degradation
Table 3 e Degradation percentages of constituents at room conditions of daylight and darkness during 6 months of stability trial (n ¼ 3).
t0 Room condition (daylight) Room condition (darkness)

























Chlorogenic acid 5.0 ± 0.14 5.1 ± 0.5 (3.0) 5.2 ± 0.7 (3.8) 5.2 ± 1.7 (4.6) 5.2 ± 0.5 (5.0) 4.0 ± 3.5 (18.6) 3.8 ± 0.6 (24.5) 5.4 ± 0.5 (8.7) 5.8 ± 0.7 (16.7) 6.2 ± 1.7 (24.8) 6.7 ± 0.6 (34.2) 5.0 ± 0.7 (1.1) 3.6 ± 0.2 (27.5)
Rutin 20.7 ± 0.02 20.2 ± 1.6 (2.2) 19.4 ± 1.9 (6.1) 18.6 ± 4.8 (4.6) 17.1 ± 1.2 (17.4) 16.2 ± 10.1 (21.5) 12.3 ± 1.8 (40.6) 20.7 ± 1.6 (0.4) 20.82 ± 1.9 (0.8) 20.9 ± 4.8 (1.2) 21.0 ± 2.0 (1.4) 15.2 ± 1.8 (26.3) 11.3 ± 0.2 (45.2)
Hyperoside 38.8 ± 0.06 33.0 ± 2.9 (14.9) 28.0 ± 2.7 (27.8) 26.0 ± 7.1 (10.0) 22.1 ± 1.6 (43.0) 20.3 ± 12.2 (47.5) 17.4 ± 2.5 (55.1) 34.4 ± 2.9 (11.3) 32.0 ± 2.7 (17.5) 29.6 ± 7.1 (23.7) 27.1 ± 2.5 (30.1) 19.0 ± 2.2 (51.1) 16.1 ± 0.4 (58.6)
Isoquercitrin 19.5 ± 0.32 18.0 ± 1.5 (7.7) 16.6 ± 1.8 (14.8) 15.2 ± 4.3 (33.0) 14.9 ± 1.1 (23.5) 11.0 ± 8.5 (43.5) 10.8 ± 1.5 (44.4) 19.0 ± 1.5 (2.5) 18.8 ± 1.8 (3.6) 18.6 ± 4.3 (4.6) 18.4 ± 1.7 (5.5) 13.5 ± 1.5 (30.7) 10.0 ± 0.4 (48.9)
Quercitrin 9.9 ± 0.04 9.5 ± 0.8 (3.7) 9.1 ± 1.0 (7.8) 8.9 ± 2.3 (22.0) 8.8 ± 0.6 (11.1) 8.3 ± 5.1 (16.3) 6.3 ± 1.0 (36.4) 10.2 ± 0.8 (3.4) 10.4 ± 1.0 (5.4) 10.6 ± 2.3 (7.4) 10.8 ± 1.0 (9.7) 7.8 ± 0.9 (21.1) 5.7 ± 0.2 (41.8)
Quercetin 3.2 ± 0.02 3.0 ± 0.2 (6.2) 2.8 ± 0.3 (12.5) 2.6 ± 0.9 (9.8) 2.5 ± 0.2 (23.2) 2.4 ± 1.3 (26.0) 1.8 ± 0.3 (42.7) 3.2 ± 0.2 (1.2) 3.12 ± 0.3 (2.4) 3.1 ± 0.9 (3.7) 3.0 ± 0.3 (5.0) 2.2 ± 0.3 (30.0) 1.7 ± 0.1 (47.0)
Amentoflavone 6.0 ± 0.08 5.6 ± 0.5 (6.2) 5.2 ± 0.4 (12.9) 4.8 ± 1.4 (18.7) 4.5 ± 0.4 (25.4) 3.3 ± 2.5 (45.0) 3.1 ± 0.5 (48.0) 5.9 ± 0.5 (1.8) 5.76 ± 0.4 (3.5) 5.7 ± 1.4 (5.2) 5.6 ± 0.5 (6.8) 3.9 ± 0.5 (34.6) 2.9 ± 0.1 (51.1)
Pseudohypericin 8.5 ± 0.08 6.4 ± 1.0 (24.4) 5.8 ± 0.4 (31.5) 5.4 ± 1.0 (19.6) 5.4 ± 0.8 (35.9) 5.2 ± 3.0 (38.2) 4.9 ± 1.2 (42.5) 7.8 ± 1.0 (7.8) 7.6 ± 0.4 (10.2) 7.4 ± 1.0 (12.5) 7.1 ± 0.9 (16.4) 5.2 ± 0.8 (38.6) 4.6 ± 0.3 (46.1)
Hypericin 2.9 ± 0.02 2.2 ± 0.2 (22.9) 1.8 ± 0.1 (36.9) 1.5 ± 0.3 (35.9) 1.3 ± 0.2 (53.1) 1.3 ± 0.9 (55.9) 1.2 ± 0.2 (57.1) 2.2 ± 0.2 (22.9) 1.8 ± 0.1 (36.9) 1.7 ± 0.3 (40.4) 1.6 ± 0.3 (42.9) 1.5 ± 0.4 (46.0) 1.1 ± 0.1 (62.6)
Hyperforin 69.8 ± 0.38 54.0 ± 2.3 (22.6) 44.0 ± 7.4 (36.9) 32.0 ± 4.8 (47.5) 28.0 ± 3.4 (59.8) 25.5 ± 6.9 (63.5) 21.9 ± 10.9 (68.7) 56.0 ± 2.3 (19.8) 46.0 ± 7.4 (34.1) 36.0 ± 4.8 (48.4) 25.8 ± 7.9 (63.0) 24.0 ± 12.2 (65.7) 23.5 ± 5.8 (66.4)
t0 ¼ starting point; Deg % ¼ degradation percentage; ± ¼ standard deviation.
Table 4 e Degradation percentages of constituents in 25Ce65% RH and 40Ce75% RH conditions during 6 months of stability trial (n ¼ 3).
t0 25Ce65% RH 40Ce75% RH

























Chlorogenic acid 5.0 ± 0.14 5.1 ± 0.5 (2.2) 5.1 ± 0.5 (2.6) 5.1 ± 0.3 (3.0) 5.1 ± 0.7 (3.0) 4.8 ± 2.1 (3.5) 3.3 ± 0.3 (32.8) 4.8 ± 0.5 (3.4) 4.6 ± 1.4 (7.4) 4.4 ± 1.9 (11.5) 4.1 ± 1.0 (18.0) 2.9 ± 0.5 (41.0) 2.1 ± 0.5 (57.3)
Rutin 20.7 ± 0.02 20.0 ± 2.0 (3.2) 19.0 ± 1.7 (8.0) 18.0 ± 0.8 (12.9) 16.1 ± 2.5 (22.0) 14.8 ± 5.5 (28.5) 11.0 ± 0.5 (46.6) 20.2 ± 1.8 (2.2) 19.0 ± 6.2 (8.0) 18.2 ± 7.8 (11.9) 17.5 ± 3.9 (15.1) 11.9 ± 1.7 (42.4) 9.9 ± 2.1 (52.)
Hyperoside 38.8 ± 0.06 32.0 ± 3.9 (17.5) 26.0 ± 2.5 (33.0) 22.0 ± 1.2 (43.3) 21.3 ± 3.2 (45.0) 19.0 ± 6.9 (51.0) 15.7 ± 1.0 (59.6) 31.0 ± 3.1 (20.1) 27.0 ± 9.0 (30.4) 25.0 ± 10.8 (35.5) 21.5 ± 4.4 (44.6) 14.3 ± 1.9 (63.0) 13.1 ± 2.7 (66.3)
Isoquercitrin 19.5 ± 0.32 18.0 ± 1.8 (7.7) 16.0 ± 1.6 (17.9) 15.0 ± 0.7 (23.0) 14.1 ± 2.2 (27.5) 13.0 ± 4.6 (33.1) 9.8 ± 0.5 (49.9) 17.4 ± 1.5 (10.7) 16.8 ± 5.6 (13.8) 16.2 ± 6.7 (16.9) 15.0 ± 3.1 (23.3) 10.4 ± 1.4 (46.5) 8.4 ± 1.7 (57.1)
Quercitrin 9.9 ± 0.04 9.5 ± 0.9 (3.9) 9.1 ± 0.8 (7.8) 8.7 ± 0.4 (11.6) 8.3 ± 1.4 (15.5) 7.4 ± 2.8 (24.6) 5.6 ± 0.3 (42.9) 9.5 ± 0.8 (3.7) 9.3 ± 3.1 (5.7) 9.2 ± 3.7 (6.7) 9.0 ± 2.0 (8.6) 5.9 ± 0.9 (39.8) 4.8 ± 1.0 (51.2)
Quercetin 3.2 ± 0.02 3.0 ± 0.3 (6.2) 2.8 ± 0.3 (12.5) 2.6 ± 0.2 (18.7) 2.5 ± 0.5 (22.1) 2.2 ± 0.8 (30.2) 1.7 ± 0.1 (46.9) 3.2 ± 0.1 (0.1) 3.2 ± 1.3 (0.1) 3.2 ± 1.7 (0.1) 3.2 ± 0.9 (0.1) 2.3 ± 0.3 (29.5) 1.9 ± 0.4 (40.1)
Amentoflavone 6.0 ± 0.08 5.6 ± 0.6 (6.9) 5.2 ± 0.5 (13.6) 4.8 ± 0.3 (20.3) 4.3 ± 0.7 (27.3) 3.9 ± 1.4 (35.0) 2.9 ± 0.2 (51.3) 5.5 ± 0.6 (7.9) 5.3 ± 2.1 (11.2) 5.2 ± 2.4 (12.9) 5.1 ± 1.1 (15.2) 3.4 ± 0.5 (42.8) 2.8 ± 0.6 (52.4)
Pseudohypericin 8.5 ± 0.08 7.6 ± 1.7 (10.2) 6.8 ± 0.4 (19.6) 6.0 ± 0.2 (29.1) 5.1 ± 0.2 (39.2) 4.7 ± 1.3 (44.5) 4.6 ± 0.1 (45.3) 5.6 ± 1.0 (33.8) 5.0 ± 0.7 (40.9) 4.4 ± 1.2 (48.0) 3.8 ± 1.3 (54.7) 3.0 ± 0.5 (64.4) 2.9 ± 0.7 (65.4)
Hypericin 2.9 ± 0.02 2.5 ± 0.3 (13.8) 2.0 ± 0.2 (29.9) 1.7 ± 0.04 (40.4) 1.4 ± 0.3 (51.4) 1.3 ± 0.6 (54.1) 1.2 ± 0.1 (58.5) 1.8 ± 0.1 (36.9) 1.6 ± 0.1 (44.0) 0.9 ± 0.1 (68.5) 0.6 ± 0.01 (79.0) 0.6 ± 0.1 (80.3) 0.4 ± 0.0 (84.8)
Hyperforin 69.8 ± 0.38 62.0 ± 4.0 (11.2) 58.0 ± 1.9 (16.9) 54.0 ± 4.8 (22.6) 50.86 ± 1.0 (27.1) 43.8 ± 16.6 (37.3) 40.6 ± 4.2 (41.8) 58.0 ± 7.6 (16.9) 48.0 ± 4.2 (31.2) 34.0 ± 6.1 (51.3) 27.0 ± 4.5 (61.3) 23.2 ± 4.2 (66.8) 22.0 ± 4.0 (68.5)

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 3 ( 2 0 1 5 ) 5 4 5e5 5 1550percentages were similar. Flavonoids were preserved at20C
for 4 months but not at 4C. Almost half of all active in-
gredients in the extract degraded at 4C in 6months. At20C,
pseudohypericin and hypericin content degraded 25% in 6
months. These results suggest that refrigeration could not
keep HPME stable for 6 months. Even more important, the
degradation after 6 months at 20C indicates the necessity
for storage at 80C, although this is considered not feasible
[21]. The increased amounts of chlorogenic acid and hyper-
forin in the 4th month for both conditions might be attribut-
able to the effect of analogues of the molecules to the peak
area. Further techniques of analysis are required to enlighten
this fact.
Previous studies demonstrated that important constitu-
ents of HP, hypericin and hyperforin, are unstable com-
pounds. They are known to be affected by light, temperature,
and humidity [12,13,16e23]. Constituents could even change
during the investigation and analysis step in validation
studies. Our results correlate with these findings. All compo-
nents of HP degrade to varying levels. Among them, hypericin
and hyperforin were the most fragile. Of the phenolic acids,
chlorogenic acid was more stable than flavonoids (rutin,
hyperoside, isoquercitrin, quercitrin, quercetin, and amento-
flavone). The degradation profile of HP dried total extract for
all major constituents has been shown under common con-
ditions for 6 months in this study. Even storage under cold
conditions could not preserve the constituents. Under some
conditions, the reported ineffectiveness and adverse effects
could have been due to the decay of constituents in the
extract. Analysis of these constituents need to be investigated
in further studies.4. Conclusion
The instability of the individual active constituents of H. per-
foratum L. has been emphasized in some analysis studies. In
our study, the fluctuation of the constituents of the total
extract has been demonstrated. Among the active ingredients
investigated, chlorogenic acid was generally the most stable.
As predicted, decay was lowest in 20C and highest in
40Ce75% RH for all analyzed constituents. Except for hyper-
forin, dark condition decreases breakdown within 4 months.
No significant protective effect was provided by cold condi-
tions on the dry extract for pseudohypericin and hyperoside
for 4 months. Similar decay profiles were observed both at
20C and 4C for pseudohypericin, hypericin, and chloro-
genic acid, whereas flavonoids were preserved at 20C for 4
months. However, at the end of 6 months, equivalent per-
centages of change for all constituents in all conditions show
the obvious effect of time on HPME. Previous studies on H.
perforatum extracts mainly include investigations on selected
ingredient or incomparable conditions. To the best of our
knowledge, this study is the first to cover all major constitu-
ents of the dried total extract under different possible cases to
identify the complexities on the total extract and demonstrate
the crucial breakdown of the constituents. Instability of the
compounds could vitally affect the results of ongoing analyses
and could be the reason for the inconsistency in efficacy trials;
j o u r n a l o f f o o d and d ru g an a l y s i s 2 3 ( 2 0 1 5 ) 5 4 5e5 5 1 551in addition, unpredictable interactions and side effects could
also occur.Conflicts of interest
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